Mostrar el registro sencillo del ítem

dc.contributor.authorPadin Iruegas, Maria Elena
dc.contributor.authorChamorro Petronacci, Cintia Micaela
dc.contributor.authorSines-Cajade, I.
dc.contributor.authorLorenzo Pouso, Alejandro Ismael
dc.contributor.authorBlanco Carrión, Andrés
dc.contributor.authorPérez-Jardón, A.
dc.contributor.authorGándara Vila, Pilar 
dc.contributor.authorPérez Sayáns, Mario
dc.date.accessioned2025-08-26T08:51:12Z
dc.date.available2025-08-26T08:51:12Z
dc.date.issued2022
dc.identifier.citationPadin-Iruegas E, Chamorro-Petronacci CM, Sines-Cajade I, Lorenzo-Pouso AI, Blanco-Carrión A, Pérez-Jardón A, et al. DNA Methylation by Bisulfite Next-Generation Sequencing for MLH1 and MGMT in Oral Squamous Cell Carcinomas and Potentially Malignant Disorders: An Integrative Analysis towards Field Cancerization. Medicina (Lithuania). 2022;58(7).
dc.identifier.issn1648-9144
dc.identifier.otherhttps://portalcientifico.sergas.gal/documentos/62e5c353e5f0e01a6a1d084d*
dc.identifier.urihttp://hdl.handle.net/20.500.11940/20639
dc.description.abstractBackground and Objectives: MGMT methylation is a well-described biomarker in several solid tumors and MLH1 seems to occur in the initial stages of oral carcinogenesis. The aims of this study were to evaluate MHL1 and MGMT methylation levels in oral squamous cell carcinoma (OSCC) and oral potentially malignant disorders (OPMDs), and to integrate this information with The Cancer Genome Atlas (TCGA) database. Materials and Methods: To determine the percentage of gene methylation in MLH1 and MGMT, pyrosequencing analysis was conducted. Samples were divided as follows: (1) patients diagnosed with OSCC (N = 16); (2) patients with OPDM who developed OSCC in the same location (N = 47); and (3) patients with OPDM who developed OSCC in a different location (N = 22). As a validation cohort in this study, data from The Cancer Genomic Atlas (TCGA) database, particularly regarding Head and Neck Squamous Cell Carcinoma, was used. Results: Overall MLH1 methylation levels of 8.6 ± 11.5% and 8.1 ± 9.2% for MGMT were obtained. With regard to MHL1, the OSCC presented the highest degree of methylation with 9.3 ± 7.3% (95%CI 5.1-13.6), and with regards to MGMT, the simultaneous malignancy group presented the highest degree of methylation with 10 ± 13.5% (95%CI 6-10), although no significant differences were found between the groups (p = 0.934 and p = 0.515, respectively). The estimated survival was higher for MGMT methylated cases (19.1 months, 95%CI 19.1-19.1) than for unmethylated cases (9.4 months, 95%CI 6-12.8), but not statistically significant. Conclusions: Our results did not show a correlation between MGMT and MLH1 methylation and any clinicopathological feature or survival in our institutional cohort. MLH1 methylation was present mainly in OSCC, whilst MGMT in OPMD represented a modest contribution to field cancerization, with an overall consistency with the TCGA database.en
dc.description.sponsorshipThis research was funded by a pre-doctoral grant (on a competitive basis) from the Health Research Institute of Santiago de Compostela that was awarded to Alba Perez Jardon, grant number IDIS2020/PREDOC/03.en
dc.language.isoeng
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleDNA Methylation by Bisulfite Next-Generation Sequencing for MLH1 and MGMT in Oral Squamous Cell Carcinomas and Potentially Malignant Disorders: An Integrative Analysis towards Field Cancerization*
dc.typeArticleen
dc.authorsophosPadin-Iruegas, M. E.
dc.authorsophosChamorro-Petronacci, C. M.
dc.authorsophosSines-Cajade, I.
dc.authorsophosLorenzo-Pouso, A. I.
dc.authorsophosBlanco-Carrión, A.
dc.authorsophosPérez-Jardón, A.
dc.authorsophosGándara-Vila, P.
dc.authorsophosPérez, Sayans
dc.identifier.doi10.3390/medicina58070878
dc.identifier.sophos62e5c353e5f0e01a6a1d084d
dc.issue.number7
dc.journal.titleMedicina (Lithuania)*
dc.relation.projectIDHealth Research Institute of Santiago de Compostela [IDIS2020/PREDOC/03]
dc.relation.publisherversionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322644/pdf/medicina-58-00878.pdf;https://mdpi-res.com/d_attachment/medicina/medicina-58-00878/article_deploy/medicina-58-00878.pdf?version=1656595326es
dc.rights.accessRightsopenAccess
dc.subject.keywordIDISes
dc.subject.keywordAS Coruña APes
dc.subject.keywordAS Pontevedra APes
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)es
dc.typesophosArtículo Originales
dc.volume.number58


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional